H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on iTeos Therapeutics to $46 from $44 and keeps a Buy rating on the shares following the Q1 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- iTeos Therapeutics to sell 1.14M shares at $17.50 in registered direct offering
- iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
- iTeos Therapeutics sees cash runway through 2027
- iTeos Therapeutics reports Q1 EPS ($1.07), consensus ($1.26)
- iTeos Therapeutics Announces $120 Million Registered Direct Offering